Key clinical point: Galcanezumab is safe and effective in the prophylactic treatment of adult migraine.
Major finding: Compared with placebo, galcanezumab at doses of 120, 150, 240, and 300 mg significantly reduced monthly migraine days (mean difference [MD], −1.79, −1.20, −1.85, and –0.62, respectively). Reduction in migraine-specific medication days was statistically significant for galcanezumab doses of 120 and 240 mg vs. placebo. Total adverse events did not differ significantly between galcanezumab and placebo.
Study details: Meta-analysis of 5 studies evaluated the safety and efficacy of galcanezumab in the prophylactic treatment of adult migraine.
Disclosures: No study sponsor was identified. The authors declared no conflicts of interest.
Citation: Zhao X et al. J Neurol. 2020 Jan 31. doi: 10.1007/s00415-020-09707-5 .